Bayer says NUBEQA cut risk of metastasis or death by 58% in new data
According to TradingView, NUBEQA added to ADT and radiation reduced metastasis or death risk by 58% in high-risk recurrent prostate cancer.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, adding NUBEQA to androgen deprivation therapy and radiation lowered the risk of metastasis or death by 58% in patients with high-risk recurrent prostate cancer (HR 0.42; p=0.0001). After four years, 95% of patients were metastasis-free versus 88%, and the safety profile, the source said, remained consistent.
Bayer AG (BAYN) also took part in talks during an Indian commerce visit about expanding manufacturing, research and development, and innovation in the country. According to the publication, the companies aim to double or triple growth there over two to five years.
why it matters
For markets, the trial data matter mainly for Bayer and its oncology franchise, since a strong efficacy result can shape expectations for the drug's sales. The India plans concern long-term growth, and the text gives no investment amounts or exact timelines.
market impact
Bayer AG (BAYN): trial data and India growth plans may support investor interest in the company's shares.
tags
instruments
sources
- Key facts: Bayer’s NUBEQA Cuts Risk 58%; Bayer AG (BAYN) Eyes India — TradingView, 25 October 2026 at 05:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗